Good morning, good afternoon, good evening, everyone. Thank you for joining us today. My name is Andra Axente. I'm the Integrated Communications Leader at DeepHealth, a RadNet company, and I have the pleasure of moderating this event. We're here together to share more insights on the transformative milestone that we announced today for the radiology industry, RadNet's acquisition of Gleamer to be integrated into DeepHealth. Today's session is an opportunity to hear insights from leaders across the three companies on the strategic rationale, the shared mission, and what this integration will mean for the future of healthcare. Please share your questions in the question box that you see on the webcast, and we will address them in the Q&A section. Before we begin, please note that throughout the session, we will be discussing forward-looking topics. Therefore, we encourage you to read our forward-looking statements. I'm very pleased to introduce our speakers today. First of all, Greg Sorensen, Chief Strategy Officer at RadNet, Kees Wesdorp, President and CEO, DeepHealth, Christian Allouche, Co-founder and CEO, Gleamer, Sham Sokka, Chief Operating and Technology Officer at DeepHealth, and Niccolo Stefani, Business and Product Leader, Population Health and Clinical AI. With that, Greg, take it away. Thanks very much, Andra. Let's go ahead to the next slide, where I'm gonna introduce a little bit about RadNet, for those of you who may not be familiar with us. RadNet is a national leader in outpatient radiology imaging in the United States. It is the largest outpatient imaging chain in the U.S., with over 425 imaging centers. We partner with inpatient hospital chains. We have 26 of these joint venture partners to help broaden the portfolio of services that we can offer and the patients that we can serve. RadNet's size gives it a number of unusual features that I just wanted to sort of help set the stage for why this acquisition will be so transformative. We're a really unique opportunity in that we vertically integrate, a provider, and in fact, as you'll see, a very large provider organization, with a transformative technology leadership. That combination is really unique in the industry and allows us to do things that are, I think, very impactful for human health. Part of the way we do this is this large team of radiologists. We have over 1,000 radiologists on contract. What I really wanted to highlight today is we at RadNet do a lot of routine imaging, lots of ultrasound, lot of plain films, lots of mammography, the things that are the bread and butter of radiology. I'm a radiologist myself, and it's easy to get enamored with the very sophisticated and really groundbreaking advanced imaging tools we have. Really, the core of our business is providing routine imaging services. Strengthening that core is what this acquisition is largely about. Specifically, RadNet does about 2 million mammograms a year. We're here in France. The best data that I can see is that France, as a whole country, does about 3 million mammograms a year. This gives you a sense of the kind of innovation scale at which our teams can work. Once we innovate something, just rolling it out inside RadNet, forget about other customers that we'll talk about, that alone has tremendous impact and opportunity for insights and innovation. We also do, at RadNet, a ton of other advanced imaging, as you can see on the slide here. We're very focused, in the nine states that we operate in on equitable care. We serve a lot of traditionally underserved minority populations. Now, because RadNet is at such a scale, for years now, we've been very interested in the advances in artificial intelligence to help us improve the care that we deliver. Andra, on the next slide, if you could advance, I just wanted to highlight quickly three big problems that we see that we think other parts of the healthcare system see throughout the world. It's difficult to connect with patients in many countries, in many markets. Building better tools so our patients can receive the care they need seamlessly is a big part of our goal. Every provider I know, every provider organization I know around the world is dealing with workforce shortages. Labor shortages are a real problem. There are inconsistent clinical outcomes as different providers have different levels of competence. All of these are problems that technology could help us address, and all of these problems, if addressed, could lead to substantial improvements in care and in savings. It's for this reason that we at RadNet have advanced into digital health and are trying to take advantage of these amazing new things in AI. On my next slide, then I just wanna highlight specifically this move into routine imaging. I've already highlighted how much routine we do in mammography and ultrasound, but that's not just important for us, that's important for the whole world, as you can see from these statistics here. It's really the excitement that leads us here today and the opportunities that we have with Gleamer, both to improve outpatient care, but also acute care and help radiologists around the world. With that, let me turn it over to you, Kees, to talk about why DeepHealth and Gleamer. Thank you, Greg. Let me start off that I'm very, very excited about the time that we operate in and the opportunity that we have at hand with the fantastic company that Christian and his team has built over the last couple of years. Our mission is to empower breakthroughs in care through imaging, and obviously, the opportunity that we have between DeepHealth and Gleamer only underlines that. In the next slides, I've quantified that a little bit more in detail. We consider ourselves a global leader in AI-powered health informatics, and I would say now we're the undisputed leader in terms of the solutions that we provide. For instance, in terms of customer reach, we can now say that we jointly serve over 2,700 customer contracts worldwide. We have a global footprint of 550 employees and teammates. We have increased our clinically validated portfolio with 26 FDA cleared and 22 CE marked solutions covering over 75 indications. Obviously over time, we've integrated capabilities that started with the journey of the company that Dr. Sorensen has founded, that was originally called DeepHealth. We've added to that lung, prostate, we already had the risk and PACS portfolio within DeepHealth. We further strengthened the mammography space with the acquisition of Qure.ai and iCAD. We've last year dipped into the opportunity of ultrasound with thyroid solutions and now also developing that for breast. We've acquired CIMAR, which is an image exchange platform, underlining the importance between the marriage between clinical AI and IT infrastructure. Obviously today we're gonna talk about the acquisition, the strategic acquisition of Gleamer. All of this obviously is what forms DeepHealth today. Before going further in details on the specifics of the acquisition, on the next page, you'll see our unique position and capabilities lined out. You might have heard me talk previously about the fact that we're vertically integrated. I wanna bring that home once more because the unique symbiosis and the partnership that we have with the RadNet services business allows us to very quickly, validate, prototype and validate and deploy solutions, learn from that, and improve them in a way that no other competitor can, both in terms of time to market as well on specificity of what these solutions can offer. We're clinically proven. Jointly with Gleamer, we have over 3,000 healthcare provider locations worldwide, and we're delivering at scale. Think of over 50 million supported imaging studies per year. We've become from what is a technology platform delivering impact to an at-scale solutions provider across a multitude of solutions. I'm gonna hand over to Christian, who's gonna talk a little bit more about the fantastic company he has built, and the opportunity that we have jointly had. Thank you, Kees. Gleamer is one of the fastest growing startup in this ecosystem. We've been growing at a pace superior to 90%, a year-over-year growth rate of our ARR superior to 90%. That has been consistent for the past four years. The roots of Gleamer are within X-ray and within Europe. It's a Paris-based startup, which today has most of its installed base in Europe and in the rest of world, which make a unique opportunity, by the way, to combine our forces with DeepHealth and RadNet, to have a broader coverage over all the continents today. Initially, we started this journey by building strong AI solution in X-ray and rapidly expanding to mammography, CT, MR, and notably through several M&A acquisition. Today, we are combining our resources, and we are combining our team to make the best company in this market, and working towards building a reporting solution to make sure we can unlock new productivity gain for the radiology of the future. Thank you, Christian. If you go to the next page, I would like to underline the four reasons why we have such a high conviction that the strategic combination of Gleamer and DeepHealth makes so much sense. Probably where I wanna start off with is the impact it has on our portfolio. This allows us to go even deeper into routine imaging and acute care. Nico and Sham will further explain that in terms of scope that we'll jointly offer. The second is that this will accelerate our commercial reach and scale. I've already mentioned the over 2,700 combined customer contracts. It's also the addition of a very, very strong commercial team from Gleamer, with over 50 employees actively involved engaging with customers with the installed base and providing significant upsell and cross-sell opportunities. The third reason is the opportunity of driving operational efficiency across RadNet's highest volume workflows. Obviously, clinical AI solutions, workflow solutions will have massive impact in terms of addressing the workforce shortages that Greg was talking about, or being more specific in your diagnosis for better outcomes and care. Last but not least, the vision of Christian and team and our vision of moving towards automated roadmaps, not just looking at detection and diagnosis, but also thinking about how you can improve case triaging and case prioritization, how you can improve automated reporting is something that is, that we see, have a very similar vision on. The combination will accelerate the roadmap towards automated diagnostics as we move forward. If you go to the next page, let me give a little bit more dimensions of the scale that we're bringing together. We're really bringing together two unique leaders. We've reported today on our 2025 results for DeepHealth, so this is without Gleamer. $93 million in revenue, $75 million of that is ARR, annually recurring revenue, a high degree of subscription within our business already. We've shown 35+% recurring revenue growth. Now look at Gleamer and what we're projecting for 2026. We're seeing the opportunity to capture $30 million of annual recurring revenue on the Gleamer perimeter. That comes, as Christian says, with a fantastic track record of 90% annual recurring revenue growth over the last 4 years. If you then look at what we've guided on in 2026 as part of our earnings call today, the combination is guided to deliver $135 million-$145 million in revenue, $120 million-$140 million of ARR, and that implies an 80%-90% ARR growth. We're now gonna dive a little bit more deeply into the opportunity that we have in terms of capturing synergies and the value of the combination. I'm gonna hand it over to Sham to elaborate on that. Yeah. Thanks, Kees. You know, we're really quite excited about the one plus one is five sort of combination. I think as you look at the many synergies we have, they really group into sort of three areas. One is product synergies, as both Kees and Christian alluded to, with complementary products in different modality areas. We also have complementary clearances. Gleamer has clearances in Europe that sort of complement the clearances of DeepHealth in the U.S., so we can address more markets as well as with more variety of products and offerings. We'll be talking through those in the coming months. It also allows us to accelerate the roadmap very much, bringing the R&D teams and the product teams together, getting into new areas, so expanding the portfolio beyond what we're doing currently and also getting some speed on things that are foundation model-based, things that are like automated reporting and so forth. That's the first area. The second area is around commercial synergies. We see that there's an opportunity on the commercial side to increase the let's say, the standalone of both and to bring together a $7 million-plus revenue run rate increase. We see attractive cross-selling and upselling opportunities, you know, DeepHealth products being brought into the Gleamer portfolio and Gleamer Copilot combinations, as well as vice versa in markets and in customers where DeepHealth is already ongoing. We can bring Gleamer products into the portfolio there. We see acceleration in some of the newer markets, where we're just starting to land with distributors, both in Europe and EMEA, and there's a real opportunity for accelerating growth there. Then I think, you know, Christian and team have built a very strong commercial engine. It's really in terms of moving customers from trials to contracts to, you know, really outcomes at a high velocity. So we wanna bring some of that adoption-focused operating model across our entire portfolio. We're really quite excited about also integrating capabilities, not just products. Finally, as we both operate together, we've identified various cost synergies that sort of come out of the integration, $2 million in sort of direct savings and overlapping with vendors, so we can start to streamline some of that. You know, we have existing hiring plans in DeepHealth where the Gleamer team will fill some of those roles. There's again additional synergies there that we can start to drive on the operating margin side as well. We'll see that as we go through this year and into next year. Sham, I just, for the audience, it says on the slide European and EMEA growth acceleration. In all our excitement, that must be a typo. It's U.S. and EMEA growth acceleration. We see the cross-sell and upsell opportunities equally so in the U.S. as in EMEA. I just wanted to clarify that. Yeah. Absolutely. If you move to the next slide, Andra. Gleamer brings to DeepHealth really significant capabilities in R&D, in product, in some of the functions as we talked about, the engine, if you will, and of course, in the commercial side, about 131 employees, about a little over 70 employees in R&D, so really strengthening the R&D side, and about 40 employees on the commercial side, really both in Europe and in the U.S. Also allows us to augment our commercial scale as we go forward, and really excited about bringing these two teams together. Already had numerous discussions about how we can leverage new growth opportunities together, right? That really speaks to where we're going, right? I think this is the excitement, Andra started us with, really transformational. You know, if we look today, we're really at the very, very early stages of AI. You know, if you look at all the product portfolios in the industry, we're really only covering, together maybe 10%, maximum of all the different types of things we could do. What we really aim to do with this, with this transaction is to bring a team and strengthen a team that can really move along this sort of broader landscape, right? Moving in MR, for example, in the current sort of prostate and neuro, but adding things like musculoskeletal, which is a significant expertise of Gleamer, then for us to move into, you know, other applications, body applications in MR. In CT, again, strengthening lung, being more holistic in the lung space, covering more things than just nodules, but different disease states in the lung area, expanding into abdomen and pelvis areas. Mammography, we also strengthen our downstream capability as we move toward more automated type of reporting around screening workflows. In the X-ray space, of course, which is a traditionally not a space that DeepHealth was in, now we add a significant capability both in musculoskeletal X-ray, but also in chest X-ray, we really hope to bring that through RadNet integration and deep deployment there into a more automated draft reporting and type of workflows. Really we're at the beginning of this and with Gleamer now, we really wanna move that journey toward much more of a automated radiology context over the next three to five years. That brings us to today, if you move to the next slide, Andra, to where we are entering the market today already with a very rich portfolio, and what we'll now start to be going to market with. Let me hand it off a little bit to Nico, who's gonna talk a little bit about our product portfolio and how this really grows expansion of what we're doing in this space. Thank you, Sham. If now we, you know, we start to put some attention on really the enlarged portfolio is that, first of all, I think as, you know, was said before, this position us today with the Gleamer acquisition as the larger radiology AI provider worldwide. That's, I think, of course, a great achievement that we are all excited about. And what we are more excited is really what we can bring to our customer and of course, their patient. If you look now where we start with Population Health & Clinical AI, we aim really to influence the three main pillar in the healthcare, you know, stage shift diseases, so how we of course like detect disease earlier. We want to do that in an optimized in diagnostic process. How we really lower the cost of diagnostic and diagnosis, and as well as how we bring innovation to more and more patient. In the population health, we were focusing on of course, like screening mainly and some chronic disease. Now, as also, you know, Greg mentioned before, we are going with the Gleamer acquisition to also include all routine imaging and in both setting, like acute setting as well as, you know, chronic setting. Covering hospital, imaging center, a large breadth of really like patient population. These actually will accelerate of course, the reach we have our solution, and as I said before, deliver a, you know, the larger portfolio that we have today in the market. If you see the indication that now we cover with the combined portfolio is more than 75 in-indication across multiple specialty. That's really like what make now today all of us unique. So if you go to the next slide to bring like a, I think, a real life example, as you know, Greg mentioned of course some number at RadNet, but today at RadNet, we do around 2.8 million X-ray. Okay? So when we look what we can do right now to with the, of course, the DeepHealth Gleamer solution combined, is that we can really bring an impact in four main pillar. So we can of course accelerate the turnaround time of the exam itself. We can enhance radiology efficiency because as we said before, it's not only about detection, but it's all about also can we optimize the workflow, basically allow the some sort of triage. The AI can be used for detection, but also to flag the exam that actually need more attention now based on the finding of the AI. Can we optimize that kind of workflow even before the radiologists look at the images? Also as well, what is more important, we said that it's shortage of radiologists. You want the specialist to be really focused in the exam that maybe they are more difficult and, you know, having all this finding and the AI helping triage also towards the right person to read the examination, that of course made an impact for the experience of the radiologist and more important for a more, let's say, standard and a better outcome for the patient. All of this together can bring this like automated workflow that can hopefully today and in the future, drive more automation between interpretation and reporting. All of these, if you combine with the fact that 2.8 million X-ray is around 25% of really what is the annual imaging volume around an X-ray, even if you improve some of these, let's say, workflow of, you know, 5%, 6%, the impact will be, you know, of course like major. That's why we think that with that and with implementation of the new solution at RadNet, we can bring a short time improvement and really like deliver a better experience for our care team and for their patient. If you go to the next slide, and I think what we are all excited is that in two days from now, we are launching this at ECR as one company. We have two DeepHealth booth, where we have of course, a combined team, in both booth and where we are going to showcase the combined portfolio. Again, we are looking forward to of course, you know, whoever want to know more and of course to all of our customer as a one company today sharing the excitement for the acquisition. Thank you so much to all the speakers for the very insightful content that you've just presented. This is clearly a very exciting new chapter for all. Thank you also for the questions that you've shared throughout the session. We're opening up the Q&A where I will be reading through some of the questions and direct them to some of you. Of course, feel free to jump in and add any additional insights that you would like. We'll aim to get through as many questions that we can in the time that we have. If we don't get to your questions, we'll make sure to follow up. Let's start with the first one. How will Gleamer products be integrated into the DeepHealth product portfolio? You've touched upon that, but maybe you can, share a little bit deeper. Nico, would you. Yes. first start? Thank you for the question. I think as we said, now our priority is of course our customer, now our combined customer. Okay? The first step in priority is that we don't want to bring any disruption. Okay? It's really focused on, okay, how we make sure first that we serve our customer, like really nothing happened. What more important is that we're gonna really merge, the best of both company, and I really want to use the word merge, as we have done also with previous acquisition, to really bring the best of the best that the combination of both company can bring to them. Again, no disruption. You know, we're gonna get some times to make sure to define how really, you know, we match the best of both product. Again, we're not gonna slow down. We're gonna go straight, and we're gonna really deliver as many solution to our customer as we can. Maybe, Christian, you want to add? Yeah, exactly. I'm fully aligned. During the transaction discussion, a lot has been discussed in a very granular way on how we can make the most of these two assets. At a granular level, per product. The big question is, as Sham said, we just unveiled 10% of radiology, the real question is what are we going to build together? This is where all our intention is now focused on. We are going to keep serving all our customer in a better way with more product to come. Yeah, Christian Allouche, maybe if I can add a little bit. I think it's not about just even the products that we have, but the fact that it's on one stack. You know, if you're now a DeepHealth customer, the access you're gonna have and the speed to access of new solutions and products, and that's really what we're focused on, right? Thank you, all. Second question that we'll address: How is the acquisition advancing the path toward automated diagnostics? Maybe Sham, and you could maybe start, and then, others could add. Yeah. As I started earlier, I think kind of the core... Let me maybe unpack this word. You know, automated diagnostics, it means different things to different people. I think what we're really going after is, you know, just take something like X-ray, which the Gleamer team is an expert in. You know, from some accords there's 60, 80, 100, 200 findings on an X-ray, and we're building devices that find one, two, five, six. When we talk about automated diagnostics, it's how do we actually look at the broader set of findings? How can we cover those findings in a report generation? How can that report generation then lead to a clinical recommendation? Make it easier, not only for the radiologist to report, but for the referring physician to do their action, their next best action. I think a lot of the solution areas that we're working in, where, yes, we wanna make the reporting easier for radiologists, but we also wanna make the downstream decision-making easier, right? Like what we do in breast cancer screening, right? Breast cancer products that will not only help doctors find, detect cancer better, but what to do with women that are in high dense breast conditions, what we might wanna do with women that are at high risk. So this notion of automated diagnostics is both reporting and allowing radiologists to be more efficient, but also the outcomes and the pathways that they're in come afterwards. Yeah. If I could just build on that a little bit, Sham. I'd like to riff on something Howard Berger said on the earnings call this morning. People talk in other industries about AI disrupting things. Mm-hmm. While I think Geoffrey Hinton's prediction back in 2015, 2016 that we should stop training radiologists has clearly been proven to not be correct, we certainly need radiologists. We also know from the work over the last decade from many groups that in certain, in certain sort of niche areas, like, say, reading a mammogram or trying to detect a cancer, that the AI actually can outperform humans. The opportunity that we have together is to improve the quality of care, and deliver it to a greater population of people, and that is only going to happen if we can make it much more efficient. That's this automated part. The physician will be in the loop. Has to be in the loop, but they need to be... If we're going to get the kind of quality of care we want to as many kind of people as need it, we do have to change things a lot, and this team working together, I think, is the best opportunity we've seen to make that happen. It's a really transformative opportunity that we're all super excited about. Good. That's a very nice build-up for the next question. How does this acquisition position us, positions DeepHealth in the competitive landscape? Please. Yeah. Multiple ways, but Sham and Greg just talked about in terms of pursuing automation in the radiology workflow. You heard me today talk about a few metrics. For instance, our recurring revenue that combined recurring revenue into next year of, let's say, close to $140 million makes us an undisputed leader in the radiology clinical AI space. Our portfolio with combined portfolio with FDA approvals and CE marks is by far the largest, including the point around 75+ indications that we cover, is by far the largest in the industry. There are multiple metrics here that I would say set us out as an incredibly competitive and differentiated entity. Obviously the world-class team of Christian's company, the Gleamer team, only adds to that. I don't know how you would see that, Christian, but yeah. Exactly. Yeah, we are exactly aligned on this. I really do believe that we are combining already two sub-champion to become the absolute champion of this market. Where I am very happy too is that beyond merging these two install base and two commercial capabilities, we are thinking ahead of the standard in radiology and thinking what we can build to make the future of healthcare arrive now, today. Yeah. Maybe one more point, and maybe, Sham, you were going to say the same thing. Yeah. The proximity and the symbiosis that we have with the RadNet services business is not just providing us access to data, which is fantastic for our engineering platforms and learn, and deep learning algorithms and so on and so forth. It really makes fast prototyping and co-creation happening. More importantly, for everything that Greg just described in terms of the route towards more automated workflows, you need that very, very tight interplay between the clinical practice and operational practice and development, and that can only occur in settings like we have today within, or between RadNet and DeepHealth. Sure, Sham. Yeah. I was just gonna add, I mean, you know, sometimes these questions kind of get you into a trap. I mean, I don't really see this as a competitive landscape. I see this as an ecosystem that we wanna take leadership and we wanna drive, right? It doesn't mean that we're gonna not work with our partners. We are actually quite deeply working with our partners in distribution. Mm-hmm. On the AI, broader AI ecosystem. We're gonna be integrating to other PACSes. We have very good. We intend to keep doing that. I think the. We're working in the build side with several folks that have foundation models, small and large. We're gonna continue to do that. Our ambition here is to push the industry, further, and to do that at scale, and we're gonna do that very much with partners, you know, in this, in this space. Yeah. In a way, we're competing against disease. Exactly. We're not competing against other companies. Exactly. That's what we're really focused on, is beating the disease. Correct. That actually brings us to the end of this event. Thank you so much to all the speakers, as well as everyone that's joined us online. The recording of this session will be available in the website that you've accessed this live session, and the presentation will be accessible as well. If you are interested in follow-up conversations with our leaders, please do not hesitate to reach out to me. Again, thank you everyone for joining today. We look forward to this exciting new chapter for all.